Spontaneous chromosome aberrations (CA) were analyzed in 3 Fanconi's anemia (FA) patients, 8 family members, and 9 healthy individuals. Peripheral blood lymphocytes obtained from each individual were cultured and cytogenetic analysis was performed on standard and sequential G‐banded metaphases. The numbers of abnormal cells and breaks were found to be higher in AF patients compared to the other groups (p< 0.0001). Breakpoint distribution was statistically analyzed considering the formula proposed by BRØGGER (1977), showing a non‐random pattern among FA patients but not among controls or relatives (p< 0.001). Five chromosomal bands located at 1p36, 1p22, 1q21, 3p14, and 3q21 were non‐randomly involved in spontaneous CA in FA patients. These bands were correlated with the chromosomal location of fragile sites, oncogenes, and breakpoints involved in cancer‐rearrangements. A significant correlation with the location of fragile sites (p < 0.03) and breakpoints involved in cancer‐rearrangements (p < 0.001), particularly with AML chromosome anomalies (p < 0.03) was found, suggesting a possible relationship with the high predisposition to cancer observed in this disease.
The factor VIII gene (F8) intron 22 inversion (Inv22) is a paradigmatic duplicon-mediated rearrangement, found in about one half of patients with severe hemophilia A worldwide. The identification of this prevalent cause of hemophilia was delayed for nine years after the F8 characterization in 1984. The aim of this review is to present the wide diversity of practical approaches that have been developed for genotyping the Inv22 (and related int22h rearrangements) since discovery in 1993. The sequence—Southern blot, long distance-PCR and inverse shifting-PCR—for Inv22 genotyping is an interesting example of scientific ingenuity and evolution in order to resolve challenging molecular diagnostic problems.
1 February 2014 in Blood Cells, Molecules, and Diseases
CD26 + leukemic stem cells (LSC) are a specific marker for chronic myeloid leukemia (CML), absent in healthy individuals and other myeloid neoplasms. These cells can contribute to disease resistance, as they are believed to sustain the leukemic clone despite effective tyrosine kinase inhibitor (TKI) therapy. This study analyzed CD26 + LSC and BCR::ABL1 transcript levels simultaneously using multiparametric flow cytometry and RT-qPCR in 210 chronic-phase patients undergoing TKI therapy and 31 patients in treatment-free remission (TFR). A significant decrease in LSC levels was observed as patients achieved deep molecular response (DMR, BCR::ABL1IS ≤ 0.01%) (χ2, p < 0.001). However, 19% (14/73) of DMR patients displayed persistent CD26 + LSC, suggesting a quiescent state without detectable BCR::ABL1 transcripts. A weak correlation (r = 0.187, p = 0.046) between LSC/µL absolute number and BCR::ABL1 transcript levels indicates a limited predictive value between these two variables. In TFR patients, LSC recurrence during follow-up did not correlate with molecular relapse, questioning their clinical relevance in this setting. In conclusion, while CD26 + LSC are frequently observed in patients with poor molecular response, their levels significantly decrease as patients achieve DMR. However, their persistence or recurrence in TFR lacks prognostic value for molecular relapse, indicating that CD26 + LSC are not reliable predictors of outcomes in CML.